P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

Phase 1 Active not recruiting 275 enrolled Poseida Therapeutics, Inc. Roche-Genentech · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).

Timeline

Start: 2022-05-05
Primary completion: 2029-03
Completion: 2042-03

Publications

Tseng H, Dholaria B, Cranert SA, Richter M, Marquez KS, Cho BS, Bacong A, McArthur K, Eskew JD, McCaigue J, Haag S, Krasny A, Solimine B, Coffey MJ, Loyola A, Kwong J, Shune L, Kin A, Costello CL, Kocoglu MH, Ramakrishnan A, Namini H, Martin CE, Belani R, Coronella J, Shedlock DJ. TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial. Nat Commun. 2025 Nov 24;16(1):10050. doi: 10.1038/s41467-025-65267-0.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	P-BCMA-ALLO1	Cell therapy	—	Intravenous
Background	Methotrexate	Small molecule	—	Intravenous
Background	Rimiducid	Other / unclassified	—	—

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

Summary

Timeline

Publications

Drugs

Indications